“We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” Stéphane Bancel, CEO of Moderna, said in part in a company announcement posted Thursday.
The company also said it expects to complete a submission for full approval of its COVID-19 in August, and has finished enrollment for a study exploring a refrigerator-stable vaccine that could potentially ease distribution and storage.
A recent study involving the Pfizer-BioNTech COVID-19 vaccine suggested the jab’s efficacy drops to around 84% about six months after the second dose. The study, which has not yet been peer-reviewed and was published on medRxiv, was supported by Pfizer and BioNTech, concluding that despite “a gradually declining trend in vaccine efficacy,” it still was “highly efficacious in preventing COVID-19.”
Fox News’ Alexandria Hein contributed to this report.
This is a developing story, please check back for updates.